Spots Global Cancer Trial Database for small molecule
Every month we try and update this database with for small molecule cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of TRC102 in Combination With Pemetrexed in Cancer Patients | NCT00692159 | Neoplasm | TRC102 + pemetr... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors | NCT02015065 | GIST | Vandetanib | 3 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | NCT06149481 | Metastatic Colo... | Retifanlimab Therapeutic CEA... N-803 SX-682 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | NCT06149481 | Metastatic Colo... | Retifanlimab Therapeutic CEA... N-803 SX-682 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients | NCT00055380 | Cancer | Oral cytobrushi... | - | National Institutes of Health Clinical Center (CC) | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors | NCT06403436 | Advanced Solid ... Adult Solid Tum... Adult Disease Cancer | TT125-802 | 18 Years - | TOLREMO therapeutics AG | |
| BAY73-4506 Probe Substrate Study | NCT01287598 | Neoplasms | Regorafenib (St... Warfarin Omeprazole Midazolam Rosiglitazone | 18 Years - | Bayer | |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | NCT06149481 | Metastatic Colo... | Retifanlimab Therapeutic CEA... N-803 SX-682 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors | NCT06403436 | Advanced Solid ... Adult Solid Tum... Adult Disease Cancer | TT125-802 | 18 Years - | TOLREMO therapeutics AG | |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | NCT05954312 | Advanced Solid ... | VVD-130037 | 18 Years - | Vividion Therapeutics, Inc. | |
| Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients | NCT00055380 | Cancer | Oral cytobrushi... | - | National Institutes of Health Clinical Center (CC) | |
| AMG 386 and Abiraterone for Advanced Prostate Cancer | NCT01553188 | Prostatic Neopl... Prostate Cancer Neoplasm, Prost... Neoplasm,Prosta... | AMG 386 Abiraterone Prednisone | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | NCT05371054 | Lymphoma Non-Hodgkin Lym... NHL Hematologic Mal... Lymphoid Malign... | Vysis LSI MYC B... venetoclax VIP152 prednisone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | NCT06188208 | Advanced Solid ... Advanced Hemato... | VVD-130850 Pembrolizumab | 18 Years - | Vividion Therapeutics, Inc. | |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | NCT05371054 | Lymphoma Non-Hodgkin Lym... NHL Hematologic Mal... Lymphoid Malign... | Vysis LSI MYC B... venetoclax VIP152 prednisone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | NCT04890093 | Sarcoma, Ewing Rhabdomyosarcom... | PEN-866 Vincristine Temozolomide | 12 Years - 39 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
